Altimmune Inc.

11/09/2026 | Press release | Distributed by Public on 11/09/2026 12:07

Poster: Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Altimmune Inc. published this content on November 09, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 09, 2026 at 18:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]